BMS-754807

Catalog No.S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Size Price Stock Quantity  
USD 180 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Features Muti-inhibitor of the IGR-1R/IR family.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal M365U2tqdmG|ZTDhd5NigQ>? MYfpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR|UxKD1iMUPuUUk> M{jWdFE6Pzd6MEK0
IGF-Sal NXnzfYt1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWrJR|UxRTdibl2= NGDoUZUyQTd5OECyOC=>
CCRF-CEM (ALL) MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIPQNJh,PSEQvF2= NHrrU4RFVVOR M4TVdGlEPTB;MT6yN|kh|ryP Mn\GNVk6QTZ{N{K=
PC3 M1\Y[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4DVUp42KM7:TR?= NELQU21FVVOR MmDGTWM2OD1yLkm2OUDPxE1? NF3lWGkyQTl7NkK3Ni=>
JD MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVP+OUDPxE1? NFrqc29FVVOR MlPGTWM2OD1yLkO5NUDPxE1? MmCzNVk6QTZ{N{K=
DU145 NGi4dHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NESzbWl,PSEQvF2= NHTHNYFFVVOR MXfJR|UxRTFwNE[1JO69VQ>? MkKyNVk6QTZ{N{K=
KAG M3q1dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnvXglUh|ryP M2nadGROW09? NYT3NZFtUUN3ME2xMlY3PSEQvF2= MnjTNVk6QTZ{N{K=
K-562 (CML) MnfDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWT1WYtOhjVizszN MUXEUXNQ MknETWM2OD1{LkOwNkDPxE1? NXzR[XI5OTl7OU[yO|I>
B6-P210 (Murine ALL) NY\qTJZ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFfBeGd,PSEQvF2= M1vTdmROW09? NX3y[GZDUUN3ME2xMlI6OyEQvF2= NF7u[2cyQTl7NkK3Ni=>
LN CAP-FGC MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYX+OUDPxE1? M4PlSWROW09? M3L3TGlEPTB;MT60N|Qh|ryP NILLUW8yQTl7NkK3Ni=>
VW Mn3hS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnznglUh|ryP NETicoxFVVOR M{OxOWlEPTB;MD6wNVkh|ryP MnLQNVk6QTZ{N{K=
MV411 (B Myelomonocytic) MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3Lwbp42KM7:TR?= MVPEUXNQ NF;MTppKSzVyPUCuN|Mh|ryP NX65cFYyOTl7OU[yO|I>
MDA-PCa-2b MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkTlglUh|ryP NFjNNIpFVVOR MX3JR|UxRTBwMEm4JO69VQ>? NX\SV4VZOTl7OU[yO|I>
LG MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2H5dp42KM7:TR?= M2PnbGROW09? MWLJR|UxRTBwMEO4JO69VQ>? NI\iWGkyQTl7NkK3Ni=>
RS411 (B cell precursor-ALL) NF:zXGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NI\xS3J,PSEQvF2= MUTEUXNQ NVLBS21iUUN3ME2wMlExOiEQvF2= NXXVWIhPOTl7OU[yO|I>
22-r-1 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4PSfp42KM7:TR?= MYnEUXNQ NXLF[GJHUUN3ME2wMlE4PSEQvF2= NFX6PGYyQTl7NkK3Ni=>
5838 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlnJglUh|ryP NV3oUmh4TE2VTx?= NVjzT45qUUN3ME2wMlA{PCEQvF2= MVOxPVk6PjJ5Mh?=
P388 (Murine) NHHMWHlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+OUDPxE1? NHfw[|VFVVOR NFTo[npKSzVyPUSuNlch|ryP MojYNVk6QTZ{N{K=
A2780/S M{HxVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXPoUmp1hjVizszN NIHxXJRFVVOR NVzoWXJUUUN3ME2wMlEzOiEQvF2= MWixPVk6PjJ5Mh?=
RDES NUfGXZp7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEi0OJJ,PSEQvF2= NXzBU20zTE2VTx?= M{P2WWlEPTB;MD6wNVIh|ryP M{XzNFE6QTl4Mkey
B6-T315I (Murine B-ALL) NFT4NIJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXjyRplXhjVizszN NF[1PZRFVVOR MnrJTWM2OD1{LkizJO69VQ>? M2mybVE6QTl4Mkey
TOV 112D NWLVcoJyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4XnT542KM7:TR?= MmX5SG1UVw>? M3Gy[WlEPTB;Mj6xOFYh|ryP MUCxPVk6PjJ5Mh?=
TC32 M{f0R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlLpglUh|ryP MlvzSG1UVw>? MVrJR|UxRTBwMEC4JO69VQ>? MVOxPVk6PjJ5Mh?=
HL60 (acute myelocytic) NWrTPGpMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEHKO5d,PSEQvF2= M3\OWmROW09? M3fWWWlEPTB;MD6xNkDPxE1? NIXFcYcyQTl7NkK3Ni=>
TOV 21G MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXT+OUDPxE1? MVXEUXNQ MYHJR|UxRTRwMke5JO69VQ>? NUfsbGU4OTl7OU[yO|I>
TC71 M2faXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M37OeZ42KM7:TR?= MlvkSG1UVw>? MUHJR|UxRTBwMEG0JO69VQ>? MlTBNVk6QTZ{N{K=
HPN-ALL (T-cell) NFSxW5NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NELsem5,PSEQvF2= M2nkcWROW09? MmO4TWM2OD1yLkWyJO69VQ>? NX\hXJJDOTl7OU[yO|I>
A2780R MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFPMU5N,PSEQvF2= M1rO[mROW09? MlHPTWM2OD1zLkW2OEDPxE1? NIXl[oYyQTl7NkK3Ni=>
Rh1 NU\ibWgyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX7WUndThjVizszN NFzmUpFFVVOR M13FSGlEPTB;MD6wNlch|ryP NHLjWoYyQTl7NkK3Ni=>
Kasumi-1 (acute myeloid) NG\6SmNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHfu[YV,PSEQvF2= MXTEUXNQ NGjCTodKSzVyPUCuNVYh|ryP NEDlN4cyQTl7NkK3Ni=>
sk-ov-3 M{TWSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVLR[WRkhjVizszN NXHublFnTE2VTx?= M4XufmlEPTB;NT6xJO69VQ>? MmHwNVk6QTZ{N{K=
ME M1[ye2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnnQglUh|ryP MYnEUXNQ NHXM[4dKSzVyPUCuNFE2KM7:TR?= MnrSNVk6QTZ{N{K=
L1210 (Murine lymphocytic) NHXGUJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml7EglUh|ryP Mm\XSG1UVw>? Mn3zTWM2OD1{LkO5JO69VQ>? MojMNVk6QTZ{N{K=
sw-626 NVnzblVYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mo\pglUh|ryP NGXTcGxFVVOR NEnEcFdKSzVyPUKuN|A3KM7:TR?= NVnLc2l1OTl7OU[yO|I>
CTR NFj4epdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfBglUh|ryP MWPEUXNQ MkPMTWM2OD1yLkK1N{DPxE1? NUnKepQ1OTl7OU[yO|I>
ML2 (Myelomonocytic) MlzLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXn6enJIhjVizszN NIHNd41FVVOR MmHwTWM2OD1yLkC5JO69VQ>? MXexPVk6PjJ5Mh?=
ovcar-3 M{S0W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVrFbpNThjVizszN MkDPSG1UVw>? MXTJR|UxRTVizszN MU[xPVk6PjJ5Mh?=
Rh36 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NID6XZN,PSEQvF2= NFvafnNFVVOR MnjrTWM2OD1zLkSzNkDPxE1? NGT3XWkyQTl7NkK3Ni=>
MOLM-13 (acute myeloid) NW[y[3hNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHjHc2p,PSEQvF2= NITZSFlFVVOR MUPJR|UxRTBwNEKg{txO NXvyXlR5OTl7OU[yO|I>
ovcar-4 MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlK4glUh|ryP MVLEUXNQ MlLWTWM2OD1zIN88US=> MYixPVk6PjJ5Mh?=
Rh41 M4LEZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3LVVZ42KM7:TR?= M4DXZ2ROW09? NHjUcHhKSzVyPUCuNFA2KM7:TR?= MYixPVk6PjJ5Mh?=
Mutz 2 (acute myeloid) M{j5TGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXn2WopshjVizszN MlzjSG1UVw>? NWPsVndxUUN3ME2xMlE2KM7:TR?= NVzFfmdHOTl7OU[yO|I>
ovcar-5 MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWj+OUDPxE1? MY\EUXNQ M1;B[WlEPTB;MD6wOUDPxE1? NHTXVYcyQTl7NkK3Ni=>
RD1 NX;ybGJlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1jGOJ42KM7:TR?= NYf0XmVxTE2VTx?= NFiwc29KSzVyPUCuNFY5KM7:TR?= MoXONVk6QTZ{N{K=
OCI-AML 2 (acute myeloid) NYPEOWhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXX+OUDPxE1? M{XrUmROW09? NX\QOmpTUUN3ME2zMlM{KM7:TR?= M{DVdlE6QTl4Mkey
786-O MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2SyW542KM7:TR?= M4nQ[GROW09? NWDHTlNwUUN3ME2xMlY1PyEQvF2= NHThR|cyQTl7NkK3Ni=>
A673 NGfqV2pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEDwS5Z,PSEQvF2= MUXEUXNQ MoLXTWM2OD1yLkSwPEDPxE1? MYGxPVk6PjJ5Mh?=
TALL-1 (T-cell) MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnfHglUh|ryP MXnEUXNQ M{TTSmlEPTB;MT6yPEDPxE1? NGHFS5EyQTl7NkK3Ni=>
151-B M4X5RWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFr0NJp,PSEQvF2= MXXEUXNQ MlvlTWM2OD1{Lk[3JO69VQ>? MVqxPVk6PjJ5Mh?=
PFSK-1 MkfiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlLqglUh|ryP NHSwXHBFVVOR M1znVmlEPTB;MD6xN|Ih|ryP MmjvNVk6QTZ{N{K=
THP-1 NIC2[VVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEL0boF,PSEQvF2= NV;lVG9KTE2VTx?= MnfqTWM2OD14LkW4JO69VQ>? NVTve5JsOTl7OU[yO|I>
HEK293 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXrVTWNthjVizszN MVXEUXNQ Mlj0TWM2OD1yLkmxOUDPxE1? MoPkNVk6QTZ{N{K=
DAOY M{jqVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUD+OUDPxE1? M1Xi[mROW09? MoG3TWM2OD1zLkm3PUDPxE1? NH\wN2cyQTl7NkK3Ni=>
SET2 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NW\1eG9lhjVizszN M4TX[WROW09? NWfHWHRZUUN3ME2wMlI6QCEQvF2= MYOxPVk6PjJ5Mh?=
HTB-46 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{PYXJ42KM7:TR?= NEXUV2pFVVOR M2H0RWlEPTB;NT6yOUDPxE1? MWKxPVk6PjJ5Mh?=
SK-NAS MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXH+OUDPxE1? MofFSG1UVw>? MV;JR|UxRTBwNEm3JO69VQ>? NFfjO5cyQTl7NkK3Ni=>
CTLL2 M4L1UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVPqN4JLhjVizszN NH7OXpFFVVOR NWq1d3JRUUN3ME6xMlAxKM7:TR?= M1HneFE6QTl4Mkey
HTB-47 NFPuPGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4G5Vp42KM7:TR?= NX3kU5g5TE2VTx?= NFrJNJZKSzVyPUKuNFU3KM7:TR?= NWLsOlNqOTl7OU[yO|I>
LAN-1 MkTLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYj+OUDPxE1? NYXQOFNUTE2VTx?= NYjkNmltUUN3ME2wMlA1KM7:TR?= MmDXNVk6QTZ{N{K=
ST486 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mmm1glUh|ryP NV61[2tvTE2VTx?= NVniNVdEUUN3ME2xMlE6KM7:TR?= M121XFE6QTl4Mkey
HS766T MkPiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3vjb542KM7:TR?= NETZRmVFVVOR M13LXGlEPTB;Mj6wNFEh|ryP MYmxPVk6PjJ5Mh?=
IMR-32 NV3CbGo2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXjXUoJWhjVizszN MXfEUXNQ M33VNGlEPTB;MD6yOlEh|ryP MXexPVk6PjJ5Mh?=
Daudi (Burkitt's) NEf2bVhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYXWVm93hjVizszN MmrySG1UVw>? NYm0b4JLUUN3ME2yMlY{PyEQvF2= MmDVNVk6QTZ{N{K=
Aspc-1 MkXkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NULJ[HZYhjVizszN NGCwT|ZFVVOR NGnuV2dKSzVyPUCuN|c6KM7:TR?= NEjSV48yQTl7NkK3Ni=>
SK-NSH M13FNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{DLV542KM7:TR?= MX7EUXNQ Mm\wTWM2OD1yLkGzPUDPxE1? NU\iU3FYOTl7OU[yO|I>
MEC-1 (Chronic B cell) MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEXzOXR,PSEQvF2= NEP3RpFFVVOR M1zheGlEPTB;Mj62N|ch|ryP MmTvNVk6QTZ{N{K=
Capan-2 Mlr1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIrRV3p,PSEQvF2= MnfDSG1UVw>? MXnJR|UxRTFwN{e0JO69VQ>? NXrufIJsOTl7OU[yO|I>
SHSY5Y NGK0Ro5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmThglUh|ryP MkO4SG1UVw>? MlP2TWM2OD1yLkGwOkDPxE1? MofENVk6QTZ{N{K=
U937 (Histioocytic) M{H3ZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MniwglUh|ryP MnS1SG1UVw>? MYDJR|UxRjVwMECg{txO MlLUNVk6QTZ{N{K=
Bxpc-1 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXz+OUDPxE1? NEHlV4VFVVOR MmDSTWM2OD1zLkmyOEDPxE1? M3vnflE6QTl4Mkey
Bxpc-3 M{SwTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmrlglUh|ryP NXT5T2s5TE2VTx?= Mk\6TWM2OD53LkCwJO69VQ>? M1\ZXVE6QTl4Mkey
HTB-92 NELsVJNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnvVglUh|ryP NIjO[|hFVVOR M4fqemlEPTB;MT6wNkDPxE1? NIXIeoMyQTl7NkK3Ni=>
OCI-LY10 (B-cell) NUTLelJiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWj0Uo9FhjVizszN M3voZWROW09? NGm3UGhKSzVyPUCuOFUh|ryP MmrsNVk6QTZ{N{K=
PANC-1 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVf+OUDPxE1? NU\SSFVLTE2VTx?= NUjqTFBPUUN3ME61MlAxKM7:TR?= NF\aeocyQTl7NkK3Ni=>
To184.T MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnXIglUh|ryP MoLySG1UVw>? MnHDTWM2OD1yLkS2PUDPxE1? M3fRXlE6QTl4Mkey
OCI-LY19 (B-cell) M3eyTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2\aTZ42KM7:TR?= NX;HS5lsTE2VTx?= NHfsTnFKSzVyPUCuOEDPxE1? M{H1NlE6QTl4Mkey
PANC-1 BM MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXTSfopFhjVizszN NVzHbG96TE2VTx?= NXfXNos3UUN3ME61MlAxKM7:TR?= NFS4T5QyQTl7NkK3Ni=>
SA-4 Ml;FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUfSTol[hjVizszN MlWySG1UVw>? NH;yTJBKSzVyPUGuN|AyKM7:TR?= M1jrRlE6QTl4Mkey
RPMI 8226 NGPOWIRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWn+OUDPxE1? MmD1SG1UVw>? NUDSSoVzUUN3ME2xMlI6OyEQvF2= NYPQWJg2OTl7OU[yO|I>
HPAF-II MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYL+OUDPxE1? M4HJdGROW09? MXvJR|UxRTBwNkS0JO69VQ>? MXSxPVk6PjJ5Mh?=
SHP-77 MlLCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUH+OUDPxE1? MlTjSG1UVw>? NWLlZnVFUUN3ME2xMlg5QCEQvF2= NXvxOodJOTl7OU[yO|I>
U266 B1 NH\jZWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnTwglUh|ryP NXrHfYR7TE2VTx?= NE\GZnBKSzVyPUGuOlY6KM7:TR?= MV2xPVk6PjJ5Mh?=
Hs700t MnjQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXj+OUDPxE1? M3L3UGROW09? NVHJfJZEUUN3ME2wMlI{OSEQvF2= MWexPVk6PjJ5Mh?=
NCI-446 M{fUTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUL+OUDPxE1? NXf6SpU5TE2VTx?= Mlu2TWM2OD1zLkG1OEDPxE1? NFn3R4IyQTl7NkK3Ni=>
H929 M2TsO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlPlglUh|ryP NYLv[o1pTE2VTx?= NWP4RYFJUUN3ME2wMlAyPCEQvF2= MmHDNVk6QTZ{N{K=
PL45 NFjXN3FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEnn[nR,PSEQvF2= MlLrSG1UVw>? NH;oe5lKSzVyPUKuNlU2KM7:TR?= NIrt[2QyQTl7NkK3Ni=>
NCI-H383 NU\5bFkxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M37tPJ42KM7:TR?= NGH6OIlFVVOR NYOz[np1UUN3ME61MlAxKM7:TR?= NIe4b4syQTl7NkK3Ni=>
JJN3 M3L1OWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3r2cJ42KM7:TR?= MUPEUXNQ MY\JR|UxRTJwNEOzJO69VQ>? NHLrTIoyQTl7NkK3Ni=>
SU.86.86 NXywboxXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFXaPGd,PSEQvF2= MUTEUXNQ NUX4TFVGUUN3ME2yMlY4OiEQvF2= MnTGNVk6QTZ{N{K=
H1299 NYnwdGlpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mkf3glUh|ryP MkC5SG1UVw>? NWXIVHdyUUN3ME61MlAxKM7:TR?= NHT2ZoEyQTl7NkK3Ni=>
MDA-MB-468 NH3pSXhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnLGglUh|ryP NHGxepBFVVOR MluyTWM2OD1yLkWwOEDPxE1? NYPMVYw5OTl7OU[yO|I>
SW1990 NH63[WdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUfkWopNhjVizszN M13nUGROW09? M1XiTGlEPTB;MD64NlYh|ryP NEDTfGoyQTl7NkK3Ni=>
Calu-6 M3L0WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoPJglUh|ryP MonTSG1UVw>? MkPsTWM2OD53LkCwJO69VQ>? NHjKN28yQTl7NkK3Ni=>
MDA-MB-231 M{\UR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXP+OUDPxE1? NUPSRZQ1TE2VTx?= MUfJR|UxRTFwNkS4JO69VQ>? MYexPVk6PjJ5Mh?=
SW-684 MoHIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX3+OUDPxE1? NVvhOnZ4TE2VTx?= MWnJR|UxRjVwMECg{txO NGDYUWIyQTl7NkK3Ni=>
H209 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmHhglUh|ryP M1vmdWROW09? MUXJR|UxRTFwMUmzJO69VQ>? NVHyU5p7OTl7OU[yO|I>
MDA-MB-231T MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn3VglUh|ryP NGW3U3ZFVVOR Ml:yTWM2OD53LkCwJO69VQ>? M{D5dVE6QTl4Mkey
HT1080/S M364dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYn+OUDPxE1? MWfEUXNQ MUXJR|UxRTBwNUOxJO69VQ>? MX:xPVk6PjJ5Mh?=
H526 0.044 M1HpOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4LQSJ42KM7:TR?= MWXEUXNQ NG\2OVhKSzVyPUCuNFQ1KM7:TR?= MVOxPVk6PjJ5Mh?=
DU4475 2.431 NXqxWVExT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1rNNp42KM7:TR?= NVPYcGtxTE2VTx?= M3viOmlEPTB;Mj60N|Eh|ryP M364RlE6QTl4Mkey
HCT116 MlvjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3HoPJ42KM7:TR?= MoK0SG1UVw>? NXr6WVllUUN3ME2wMlg2OiEQvF2= MYKxPVk6PjJ5Mh?=
M109 NG\WdmxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnXKglUh|ryP NInHRWFFVVOR Mln1TWM2OD1zLkC1OUDPxE1? NUfiXHlqOTl7OU[yO|I>
BT549 M3z2Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2PFTp42KM7:TR?= MkD3SG1UVw>? MYXJR|UxRTFwNkS1JO69VQ>? MU[xPVk6PjJ5Mh?=
HCT116/VM46 NFnSbFNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWnaVW1MhjVizszN MnfnSG1UVw>? M{LpWWlEPTB;MT63NFIh|ryP MUixPVk6PjJ5Mh?=
H460 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2\Sdp42KM7:TR?= MYLEUXNQ MlnSTWM2OD1yLke5OUDPxE1? NHPIdnkyQTl7NkK3Ni=>
MCF-7 MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDrTHZEhjVizszN MUnEUXNQ M3TYUmlEPTB;MD6wNVYh|ryP MVmxPVk6PjJ5Mh?=
GEO MlXuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmPyglUh|ryP NWWySZJPTE2VTx?= NInpb2dKSzVyPUCuN|U3KM7:TR?= MkewNVk6QTZ{N{K=
H441 0.646 NUjrbnhIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYD+OUDPxE1? NGP0OmJFVVOR MUHJR|UxRTBwNkS2JO69VQ>? M4XFSVE6QTl4Mkey
MCF-7-807R NYTOcY83T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2\pZp42KM7:TR?= M3zLUWROW09? MkHJTWM2OD1yLkS5JO69VQ>? MWqxPVk6PjJ5Mh?=
Colo205 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYn+OUDPxE1? MVvEUXNQ M2\pU2lEPTB;MD6xNFQh|ryP NGrXOXMyQTl7NkK3Ni=>
H292 NUDD[YZoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NID4R|N,PSEQvF2= NFf3UFVFVVOR NGWycmpKSzVyPUCuO|g5KM7:TR?= NVzhSmh3OTl7OU[yO|I>
BT474 (S) NH\JT4tIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{H5b542KM7:TR?= MXnEUXNQ M2nwcmlEPTB;Mj60NFMh|ryP MVuxPVk6PjJ5Mh?=
HT-29 NEHqVlBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2jYN542KM7:TR?= NVrrRVNyTE2VTx?= NHjQeY5KSzVyPUKuNVA{KM7:TR?= Mn\ENVk6QTZ{N{K=
A549 NGnU[I5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NILyb5J,PSEQvF2= Mlj6SG1UVw>? M{X3NmlEPTB;MD62O|Uh|ryP M{fHOlE6QTl4Mkey
BT474-M1 MofMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3ryN542KM7:TR?= MVzEUXNQ M2Poc2lEPTB;Mj6zOlUh|ryP MnHmNVk6QTZ{N{K=
SW480 Ml\6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4[0U542KM7:TR?= MUnEUXNQ MljLTWM2OD53LkCwJO69VQ>? MWSxPVk6PjJ5Mh?=
L2987 M2W5bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXr+OUDPxE1? MXXEUXNQ MnHCTWM2OD1yLkS0NkDPxE1? MnvWNVk6QTZ{N{K=
AU565 NUDNOmhJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2XSfJ42KM7:TR?= MXvEUXNQ NUTiNHh[UUN3ME20Mlk4KM7:TR?= NWDLfGxTOTl7OU[yO|I>
SW403 NFzZOHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWHtUmF{hjVizszN NIfkU5dFVVOR MVjJR|UxRTBwMkKg{txO MkLZNVk6QTZ{N{K=
H1437 M2jFT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn;4glUh|ryP NHq5fINFVVOR MlvpTWM2OD1yLkWyN{DPxE1? Ml;INVk6QTZ{N{K=
BT-20 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVj+OUDPxE1? NXf6bYVZTE2VTx?= M{XZbGlEPTB;Mz61OlIh|ryP NVTQN2FVOTl7OU[yO|I>
Colo320HSR MlvLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFTYb49,PSEQvF2= M1HXcWROW09? NETiOoFKSzVyPUCuNFEyKM7:TR?= MV:xPVk6PjJ5Mh?=
H2087 NUHJZXJ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? MYnEUXNQ NX;reGtlUUN3ME6xMlAxKM7:TR?= MYqxPVk6PjJ5Mh?=
HCC1419 M2D3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXL+OUDPxE1? NYfMeZhiTE2VTx?= NYO5OFZWUUN3ME2yMlUyPyEQvF2= MmLuNVk6QTZ{N{K=
WiDr NF:5OlZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlvIglUh|ryP MoTGSG1UVw>? MYrJR|UxRTBwMEe2JO69VQ>? M2LyOFE6QTl4Mkey
H661 0.573 NV;LSZJlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnXsglUh|ryP MmrsSG1UVw>? NUTGeo5vUUN3ME2wMlU4OyEQvF2= M1XnbVE6QTl4Mkey
HCC-38 NVTNZ5RrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHq2O3B,PSEQvF2= NVGxZnhzTE2VTx?= NGnYO49KSzVyPkWuNFAh|ryP MkjQNVk6QTZ{N{K=
LS174T MoXIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUCyUpFWhjVizszN MYPEUXNQ NYW5PVdDUUN3ME2wMlU{PSEQvF2= NFziO2syQTl7NkK3Ni=>
H211 M1T4Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{PkUp42KM7:TR?= NGL0WYRFVVOR NHrs[I1KSzVyPUCuO|M{KM7:TR?= MVWxPVk6PjJ5Mh?=
HCC70 NHq3T4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2n2cZ42KM7:TR?= NXfrc3ViTE2VTx?= MWHJR|UxRTFwNUWg{txO MUOxPVk6PjJ5Mh?=
SW116 M2L5WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkTOglUh|ryP NGD1UXJFVVOR MXjJR|UxRTBwME[3JO69VQ>? MX:xPVk6PjJ5Mh?=
H513 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUTzZmhWhjVizszN NUTqTHB5TE2VTx?= NUHs[5VRUUN3ME20MlQ1QCEQvF2= NIjmOGEyQTl7NkK3Ni=>
MDA-MB-157 NFG0eVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVX+OUDPxE1? MXnEUXNQ NX\qdmI6UUN3ME2wMlA{PiEQvF2= NXPjZWtnOTl7OU[yO|I>
H2052 MkHmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnvxglUh|ryP M2TTVWROW09? M{i3NmlEPTB;MT6wOUDPxE1? NWnMOYZTOTl7OU[yO|I>
MDA-MB-415 NF3HNlNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1LrUZ42KM7:TR?= NHn5WFdFVVOR NF;NVWlKSzVyPkWuNFAh|ryP MnPTNVk6QTZ{N{K=
DLD-1 NYDx[lV3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYnTb|FKhjVizszN MYPEUXNQ MXfJR|UxRTBwOUC5JO69VQ>? M3exTFE6QTl4Mkey
H2595 NFjD[5VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWL+OUDPxE1? MUfEUXNQ NUHONm5YUUN3ME20MlQ4PSEQvF2= MnT1NVk6QTZ{N{K=
MDA-MB-435S NXXofG06T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFf1Rpl,PSEQvF2= NU[xWlR5TE2VTx?= NWLScnc5UUN3ME2xMlg3QSEQvF2= NEnE[5UyQTl7NkK3Ni=>
HCT15 NVrwSIdlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1PW[542KM7:TR?= MoXrSG1UVw>? MYPJR|UxRjFwMECg{txO NFnEWG0yQTl7NkK3Ni=>
SK-Hep1 NGi5T5ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFn4XmV,PSEQvF2= M{fpZ2ROW09? MV3JR|UxRTBwMUS2JO69VQ>? NX7FOW1JOTl7OU[yO|I>
MDA-MB-436 M3PFRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWT2d5hvhjVizszN NHXHSIFFVVOR MWjJR|UxRTVwNUCyJO69VQ>? MYCxPVk6PjJ5Mh?=
KM12C NGTC[IZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmG4glUh|ryP NF3LbHNFVVOR MWDJR|UxRTBwMEW0JO69VQ>? NH35UZcyQTl7NkK3Ni=>
HEPG2 NHu5eY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnTYglUh|ryP NH7pWlNFVVOR MUfJR|UxRTBwMEK1JO69VQ>? MXexPVk6PjJ5Mh?=
MDA-MB-453 M{npfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoTjglUh|ryP MYPEUXNQ M2DIcWlEPTB;MT64Olkh|ryP M{j1NFE6QTl4Mkey
KM12SM NIm5Xm1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUH+OUDPxE1? NGrD[m5FVVOR M2TmOGlEPTB;MD6wOVkh|ryP MkPqNVk6QTZ{N{K=
1483 NFH3VINIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVL+OUDPxE1? NYTtSYtmTE2VTx?= M1rxXGlEPTB;Mj6xPUDPxE1? NHLsTHQyQTl7NkK3Ni=>
Hs578t M3zvXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2nqZZ42KM7:TR?= NGXqdW5FVVOR MYHJR|UxRTFwMki3JO69VQ>? M1nqWVE6QTl4Mkey
LS180 NFfDXVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkPHglUh|ryP NX\Vd2c2TE2VTx?= M3XsbGlEPTB;MD62PVYh|ryP NEPvUXEyQTl7NkK3Ni=>
FaDu M2rOTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH3mUoF,PSEQvF2= MWLEUXNQ M3;UT2lEPTB;MT6yO{DPxE1? NGTafZUyQTl7NkK3Ni=>
ZR-75-1 NV7xcYI4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlW5glUh|ryP MnmySG1UVw>? NVi4UXhVUUN3ME2yMlA5PCEQvF2= Ml\WNVk6QTZ{N{K=
LS513 M3;Bemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4G4Xp42KM7:TR?= NIrVSYpFVVOR NIDMT5ZKSzVyPUCuNVM2KM7:TR?= NWfO[VB1OTl7OU[yO|I>
Detroit.562 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX[5SYRXhjVizszN NIm2NHdFVVOR NGrufG5KSzVyPUGuNVQh|ryP MX:xPVk6PjJ5Mh?=
ZR-75-30 M3LFV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlHsglUh|ryP NU\5XpBCTE2VTx?= NYfZPWNsUUN3ME61MlAxKM7:TR?= NEPHXogyQTl7NkK3Ni=>
RKO-PM M3K1Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXS2fYRLhjVizszN MkOxSG1UVw>? MmT2TWM2OD1yLkKzNkDPxE1? M4PzO|E6QTl4Mkey
Cal.27 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mlu3glUh|ryP MoO4SG1UVw>? NVPKfWFVUUN3ME2yJO69VQ>? NWXoTWJwOTl7OU[yO|I>
KPL4 M{DFTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml3yglUh|ryP NInLUINFVVOR M1nrNmlEPTB;MT6yOVIh|ryP NH\PcYIyQTl7NkK3Ni=>
PKO-RM13 NGCxXnZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXjsSndmhjVizszN NYfaSGRmTE2VTx?= MV7JR|UxRTBwNEK1JO69VQ>? MVuxPVk6PjJ5Mh?=
HS.53.T M1LiXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoPvglUh|ryP MlG2SG1UVw>? MnXoTWM2OD1yLke5JO69VQ>? NIr6ZVgyQTl7NkK3Ni=>
EMT6 MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M33sfJ42KM7:TR?= MnzRSG1UVw>? Mmn5TWM2OD1yLkiwOkDPxE1? NGqwN2syQTl7NkK3Ni=>
SNU-C1 NX21O5pPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3[1b542KM7:TR?= MVnEUXNQ MmK1TWM2OD1yLkCwO{DPxE1? MV6xPVk6PjJ5Mh?=
SQCCY1 NYP2cmZiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYD+OUDPxE1? NWnpSGhsTE2VTx?= M{DTW2lEPTB;MD63PUDPxE1? MUWxPVk6PjJ5Mh?=
SW480 NYO2TJJyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUP+OUDPxE1? NYDORohKTE2VTx?= MYXJR|UxRTBwMEO3JO69VQ>? NUTWRXM2OTl7OU[yO|I>
SCC9 MkDDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHr1bYF,PSEQvF2= M4HVcmROW09? NFrRWZJKSzVyPUCuO|Uh|ryP MlvkNVk6QTZ{N{K=
SK-LMS-1 MnLLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmHrglUh|ryP NWiw[phHTE2VTx?= NUmyPINvUUN3ME2wMlY5PyEQvF2= M2DRdVE6QTl4Mkey
SCC25 M33TO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3Lpcp42KM7:TR?= NF3FRWFFVVOR MUDJR|UxRTBwNkig{txO NW\5[pR5OTl7OU[yO|I>
U87 NVexOGM2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYj+OUDPxE1? M2[zTWROW09? M4DWTWlEPTB;MD65OUDPxE1? MoSwNVk6QTZ{N{K=
SCC15 M13sNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVf+OUDPxE1? MUPEUXNQ NGTqT4RKSzVyPUCuOlch|ryP M1HseFE6QTl4Mkey
T98G NHvNc3dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmHsglUh|ryP M{XWemROW09? MWHJR|UxRTFwMkG4JO69VQ>? NX;2R2M6OTl7OU[yO|I>
SCC4 MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVf4dXBVhjVizszN M3naOmROW09? MnTQTWM2OD1yLk[zJO69VQ>? MX[xPVk6PjJ5Mh?=
U118 M{Tldmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn[3glUh|ryP NEexUpZFVVOR M{jMXWlEPTB;MT62NVgh|ryP MXGxPVk6PjJ5Mh?=
TU167 MkTHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGXNbVR,PSEQvF2= M3nDbmROW09? NV3ZfWdRUUN3ME20MlUzKM7:TR?= NYrxVlJrOTl7OU[yO|I>
NCI-H727 MmjIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3LLbp4yOOLCit88US=> M2DJWmROW09? MVXJR|UxRTR{ODDuUS=> NV;3WlltOjB|OEW3OFc>
NCI-H720 NEPYdGxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX\+NVDjiIsQvF2= MmTISG1UVw>? Mni5TWM2OD1{Lkig{txO Mmf1NlA{QDV5NEe=
NCI-H835 M4PBfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYP+NVDjiIsQvF2= MknMSG1UVw>? Ml7CTWM2OD1zIN88US=> Mnm0NlA{QDV5NEe=
NCI-H727 MWHLbY5ie2ViYYPzZZk> M1HZSJ4yOOLCit88US=> MW\EUXNQ NFzWc3FqdmirYnn0d{Bkd26|dHn0eZRqfmViSVfGNXIh[XW2b4Doc5NxcG:{eXzheIlwdg>? MYeyNFM5PTd2Nx?=
RD NY\vN4E{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnnjglEx6oDMzszN NWDk[nh1UUN3ME2xMlEzKML3TR?= NInKSI0zOTJ7OEe0OS=>
Rh41 NFG5[5lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{PWdp4yOOLCit88US=> M1XDUGlEPTB;MD6wO{DDvU1? MVOyNVI6QDd2NR?=
Rh18 MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWGyWHN1hjFy4pEK{txO NUnCOnN5UUN3ME20Mlk3KML3TR?= NEDLUo4zOTJ7OEe0OS=>
Rh30 NFf6fItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFjtXWF,OTEkgJtOwG0> MXTJR|UxRTBwMUmgxtVO MYeyNVI6QDd2NR?=
BT-12 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mnr4glEx6oDMzszN Ml7tTWM2OD1yLke4JOK2VQ>? M2XNXVIyOjl6N{S1
CHLA-266 NI\VbmFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXXpU45vhjFy4pEK{txO MWLJR|UxRTBwOEmgxtVO MXyyNVI6QDd2NR?=
TC-71 MmjUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1nRSZ4yOOLCit88US=> Mmf0TWM2OD1yLkGxJOK2VQ>? NXLp[GdLOjF{OUi3OFU>
CHLA-9 MlHBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYP+NVDjiIsQvF2= MVfJR|UxRTBwMUKgxtVO NXLqcXhkOjF{OUi3OFU>
CHLA-10 M3nQb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFXwdo5,OTEkgJtOwG0> NUnpZndDUUN3ME2wMlYzKML3TR?= MYCyNVI6QDd2NR?=
CHLA-258 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYXuUHhohjFy4pEK{txO NEjhRWtKSzVyPUCuNlchyrWP NVvDNoZVOjF{OUi3OFU>
GBM2 NXfnV5NQT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlfwglEx6oDMzszN MWnJR|UxRTFwNEegxtVO MV[yNVI6QDd2NR?=
NB-1643 M1vxWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEnqdm5,OTEkgJtOwG0> NFjmUFBKSzVyPUCuNVIhyrWP MmfDNlEzQTh5NEW=
NB-EBc1 MlSyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlnrglEx6oDMzszN NVLmR5JkUUN3ME2wMlM2KML3TR?= NVzjVI5wOjF{OUi3OFU>
CHLA-90 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUC2eIlRhjFy4pEK{txO NYLOS|hJUUN3ME2wMlc4KML3TR?= M1\pPFIyOjl6N{S1
CHLA-136 NH2xdJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWrDNZVHhjFy4pEK{txO Mk\wTWM2OD1yLkWyJOK2VQ>? M2fCflIyOjl6N{S1
NALM-6 M4PyeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4LIPZ4yOOLCit88US=> NVrpe2RYUUN3ME2wMlQ6KML3TR?= NVrZPIZqOjF{OUi3OFU>
COG-LL-317 NVnXS3lnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4KzPZ4yOOLCit88US=> MnLjTWM2OD1zLkO4JOK2VQ>? M4TOelIyOjl6N{S1
RS4;11 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH\XUm5,OTEkgJtOwG0> NX\MRmdYUUN3ME2wMlM5KML3TR?= MXSyNVI6QDd2NR?=
MOLT-4 MlnZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVPWOoQzhjFy4pEK{txO MonUTWM2OD1yLkWzJOK2VQ>? NHvZcWUzOTJ7OEe0OS=>
CCRF-CEM NWfRWVQ6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHXu[G5,OTEkgJtOwG0> MYnJR|UxRTFwMUOgxtVO M1XSfFIyOjl6N{S1
Kasumi-1 MoLIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX30XJFIhjFy4pEK{txO M1HB[WlEPTB;MT6yJOK2VQ>? NXTBboxNOjF{OUi3OFU>
Karpas-299 NUDyNFdvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mn[0glEx6oDMzszN NULPPWNJUUN3ME2xMlY1KML3TR?= NHL5eYwzOTJ7OEe0OS=>
Ramos-RA1 MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4jEPZ4yOOLCit88US=> NGHG[lBKSzVyPUGuN|EhyrWP NITMeG8zOTJ7OEe0OS=>
Rh30  Mn\rSpVv[3Srb36gZZN{[Xl? M2P3eolv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= M4jORlI2QTJ3M{e4
Rh41 NWnF[nB6TnWwY4Tpc44h[XO|YYm= MnzlbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w MorRNlU6OjV|N{i=
RD M17veGZ2dmO2aX;uJIF{e2G7 M{HrcYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= NEjYc5QzPTl{NUO3PC=>
A549 NV7ZeHpkU2mwYYPlJIF{e2G7 M{fCTVAvPeLCit88US=> NFy2XYZFVVOR M2POb4lvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v M3K2UVI3QTJ6NUe4
NCI-H358 Mn7mT4lv[XOnIHHzd4F6 NV;YVldGOC534pEK{txO M17YZmROW09? NHX3OIFqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>? NXrFT2lzOjZ7Mki1O|g>
A549 NUjWbFhxTnWwY4Tpc44h[XO|YYm= M3;ZdFAvPeLCit88US=> NHGydVFFVVOR MULjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM M3viUVI3QTJ6NUe4
NCI-H358 NEfXUZVHfW6ldHnvckBie3OjeR?= M361Z|AvPeLCit88US=> NGHKPWtFVVOR MX7jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM NXXrVGhHOjZ7Mki1O|g>
A549 NGLueYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2jGdp4yOOLCit88US=> MWXEUXNQ M{Tx[2lEPTB;MD63OkDPxE1? NWrvSnNVOjZ7Mki1O|g>
NCI-H358 M{HLUmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUL+NVDjiIsQvF2= MUfEUXNQ MVrJR|UxRTFwMEmg{txO NHrvfHQzPjl{OEW3PC=>
A549 MmfxRZBweHSxc3nzJIF{e2G7 NHXo[4gxNjYkgJtOwG0> MkHXSG1UVw>? NGXld2VqdmS3Y3XzJGFxd3C2b4Ppdy=> NVSxW29POjZ7Mki1O|g>
NCI-H358 M3W2TmFxd3C2b4Ppd{Bie3OjeR?= M4faclAvPeLCit88US=> NFviUVhFVVOR MoLVbY5lfWOnczDBdI9xfG:|aYO= Mki5NlY6Ojh3N{i=
A549 MUXGeY5kfGmxbjDhd5NigQ>? MmLxNE426oDMzszN NX;zS417TE2VTx?= NEPYZ5Bz\WS3Y3XzJJdwfW6mIHPsc5N2emV? NXLaS|hkOjZ7Mki1O|g>
NCI-H358 M3vvWGZ2dmO2aX;uJIF{e2G7 MnPiNE426oDMzszN NVSwbpNuTE2VTx?= NWjnT4tZemWmdXPld{B4d3WwZDDjcI9{fXKn MmXRNlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
In vivo BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:[1]
- Collapse
  • Cell lines: IGF-1R-Sal, RH41 and Geo cell lines
  • Concentrations: 365 nM
  • Incubation Time: 72 hours
  • Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol)
  • Dosages: 150 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.49
Formula

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy BMS-754807 | BMS-754807 supplier | purchase BMS-754807 | BMS-754807 cost | BMS-754807 manufacturer | order BMS-754807 | BMS-754807 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID